A Multi-center, Active Controlled, Pharmacokinetic, Safety and Efficacy Study of Proellex in Pre-Menopausal Women With Symptomatic Uterine Fibroids to Assess Persistence of Response
Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention
The primary outcome measure is the PK characteristics of 25 mg and 50 mg Proellex.
Andre vanAs, MD, PhD
Repros Therapeutics Inc.
United States: Food and Drug Administration
|Physician Care Clinical Research||Sarasota, Florida 34239|
|West Houston Clinical Research Services||Houston, Texas 77055|
|Advances in Health, Inc.||Houston, Texas 77030|